AbbVie registers two real-world studies for atogepant and mirvetuximab soravtansine-gynx

AbbVie posted two new observational study registrations this week, both listed as not yet recruiting.

• A UK study called "PRACTICE" (NCT07690215) will look at the effectiveness of atogepant for the preventive treatment of migraine in adult patients in the UK.¹ The trial plans to enroll approximately 200 adult participants who are prescribed atogepant by their doctors¹ in a primary care setting, with an estimated start date of 2026-09-01 and primary completion in 2028-03.
• A South Korean post-marketing study (NCT07687602) will assess the adverse events and change in disease activity of mirvetuximab soravtansine-gynx (MIRV) in participants with folate receptor-alpha (FRα) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.² The study expects to enroll around 69 participants in South Korea², with an estimated start of 2026-06-30 and primary completion in 2031-08.